Glaukos Corporation
US ˙ NYSE ˙ US3773221029

Introduction

This page provides a comprehensive analysis of the known insider trading history of Philip T Gianos. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Philip T Gianos has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:HAIR / Restoration Robotics, Inc. 10% Owner 0
10% Owner 0
US:XLNX / Xilinx, Inc. Director 0
US:EIGR / Eiger BioPharmaceuticals, Inc. 10% Owner 3,199,186
US:GKOS / Glaukos Corporation 10% Owner 0
US:IVTY / Invuity, Inc. 10% Owner 0
US:CBYL / Carbylan Therapeutics, Inc. 10% Owner 0
US:MKTO / Marketo, Inc. 10% Owner 0
US:AGTC / Applied Genetic Technologies Corp 10% Owner 11,895
US:MGNX / MacroGenics, Inc. 10% Owner 0
US:TSRO / TESARO, Inc. 2,471,701
US:TSPT / 10% Owner 1,983,884
US:ETRM / EnteroMedics Inc 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Philip T Gianos. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases GKOS / Glaukos Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GKOS / Glaukos Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GKOS / Glaukos Corporation Insider Trades
Insider Sales GKOS / Glaukos Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GKOS / Glaukos Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GKOS / Glaukos Corporation Insider Trades
Insider Purchases KALV / KalVista Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GKOS / Glaukos Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-04-14 CBYL InterWest Management Partners IX, LLC 810,000 5.0000 810,000 5.0000 4,050,000 731

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Sales KALV / KalVista Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GKOS / Glaukos Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Purchases MGNX / MacroGenics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GKOS / Glaukos Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGNX / MacroGenics, Inc. Insider Trades
Insider Sales MGNX / MacroGenics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GKOS / Glaukos Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGNX / MacroGenics, Inc. Insider Trades
Insider Purchases VERO / Venus Concept Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GKOS / Glaukos Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VERO / Venus Concept Inc. Insider Trades
Insider Sales VERO / Venus Concept Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GKOS / Glaukos Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VERO / Venus Concept Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Philip T Gianos as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Series B Preferred Stock
C - Conversion -1,538,461 0 -100.00
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Convertible Promissory Note
C - Conversion 0
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Series C Preferred Stock
C - Conversion -1,647,297 0 -100.00
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Common Stock
C - Conversion 170,028 3,355,786 5.34 7.00 1,190,196 23,490,502
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Common Stock
C - Conversion 1,647,297 3,185,758 107.07
2017-10-17 2017-10-16 4 HAIR Restoration Robotics Inc
Common Stock
C - Conversion 1,538,461 1,538,461
2017-10-13 2017-10-11 4 HAIR Restoration Robotics Inc
Convertible Promissory Note
J - Other 1,183,713.69
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Series E Preferred Stock
C - Conversion -373,803 0 -100.00
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Series D Preferred Stock
C - Conversion -464,494 0 -100.00
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Series C Preferred Stock
C - Conversion -1,615,041 0 -100.00
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Common Stock
C - Conversion 373,803 2,453,338 17.98
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Common Stock
C - Conversion 464,494 2,079,535 28.76
2016-10-12 2016-10-12 4 OBLN OBALON THERAPEUTICS INC
Common Stock
C - Conversion 1,615,041 1,615,041
2016-08-10 2016-08-09 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -4,246 0 -100.00
2016-08-10 2016-08-09 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -4,246 85,398 -4.74
2016-08-10 2016-08-09 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 4,246 40,011 11.87
2016-08-10 2016-08-09 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 4,246 89,644 4.97
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-03-31 3 EIGR Eiger BioPharmaceuticals, Inc.
Common Stock
3,199,186
2016-01-04 2016-01-01 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -7,625 0 -100.00
2016-01-04 2016-01-01 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -7,625 85,398 -8.20
2016-01-04 2016-01-01 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 7,625 35,765 27.10
2016-01-04 2016-01-01 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 7,625 93,023 8.93
2015-11-20 2015-11-19 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale -3,025 28,140 -9.71 46.65 -141,127 1,312,835
2015-08-28 2015-08-27 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise -12,000 0 -100.00
2015-08-28 2015-08-27 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -4,706 85,398 -5.22
2015-08-28 2015-08-27 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale -7,294 90,104 -7.49 42.45 -309,630 3,824,915
2015-08-28 2015-08-27 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 4,706 31,165 17.79
2015-08-28 2015-08-27 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 12,000 97,398 14.05 25.77 309,240 2,509,946
2015-08-13 2015-08-12 4 XLNX XILINX INC
Restricted Stock Unit
A - Award 4,246 4,246
2015-08-13 2015-08-11 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -4,479 0 -100.00
2015-08-13 2015-08-11 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -4,479 85,398 -4.98
2015-08-13 2015-08-11 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 4,479 26,459 20.38
2015-08-13 2015-08-11 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 4,479 89,877 5.24
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series F Convertible Preferred Stock
C - Conversion -253,390 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series E Convertible Preferred Stock
C - Conversion -151,653 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock
C - Conversion -674,510 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series C Convertible Preferred Stock
C - Conversion -1,523,809 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock
C - Conversion 2,603,362 2,603,362
2015-06-22 2015-06-18 4 IVTY Invuity, Inc.
Series E Preferred Stock
C - Conversion -56,368 0 -100.00
2015-06-22 2015-06-18 4 IVTY Invuity, Inc.
Series D Preferred Stock
C - Conversion -262,310 0 -100.00
2015-06-22 2015-06-18 4 IVTY Invuity, Inc.
Series C Preferred Stock
C - Conversion -712,291 0 -100.00
2015-06-22 2015-06-18 4 IVTY Invuity, Inc.
Common Stock
C - Conversion 1,080,272 1,080,272
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Convertible Promissory Note
C - Conversion -365,957 0 -100.00
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Convertible Promissory Note
C - Conversion -466,357 0 -100.00
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -2,145,351 0 -100.00
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -831,531 0 -100.00
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Common Stock
P - Purchase 810,000 4,619,196 21.26 5.00 4,050,000 23,095,980
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Common Stock
C - Conversion 365,957 3,809,196 10.63
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Common Stock
C - Conversion 466,357 3,443,239 15.67
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Common Stock
C - Conversion 2,145,351 2,976,882 258.00
2015-04-14 2015-04-14 4 CBYL Carbylan Therapeutics, Inc.
Common Stock
C - Conversion 831,531 831,531
2014-12-11 2014-12-10 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise X -10,000 0 -100.00
2014-12-11 2014-12-10 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale X -6,975 85,398 -7.55 46.85 -326,782 4,000,939
2014-12-11 2014-12-10 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise X 10,000 92,373 12.14 21.12 211,200 1,950,918
2014-11-06 2014-11-05 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise X -2,000 0 -100.00
2014-11-06 2014-11-05 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise X -8,000 10,000 -44.44
2014-11-06 2014-11-05 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale X -7,354 82,373 -8.20 43.91 -322,891 3,616,743
2014-11-06 2014-11-05 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise X 2,000 89,727 2.28 29.27 58,540 2,626,309
2014-11-06 2014-11-05 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise X 8,000 87,727 10.03 21.12 168,960 1,852,794
2014-10-02 2014-10-01 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise X -10,000 2,000 -83.33
2014-10-02 2014-10-01 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale X -8,333 79,727 -9.46 42.00 -349,986 3,348,534
2014-10-02 2014-10-01 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise X 10,000 88,060 12.81 29.27 292,700 2,577,516
2014-08-14 2014-08-13 4 XLNX XILINX INC
Restricted Stock Unit
A - Award 4,479 4,479
2014-08-14 2014-08-12 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -3,660 0 -100.00
2014-08-14 2014-08-12 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -3,660 78,060 -4.48
2014-08-14 2014-08-12 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 3,660 21,980 19.98
2014-08-14 2014-08-12 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 3,660 81,720 4.69
2014-06-02 2014-05-30 4 MKTO Marketo, Inc.
Common Stock
S - Sale -16,613 0 -100.00 23.06 -383,096
2014-06-02 2014-05-30 4 MKTO Marketo, Inc.
Common Stock
S - Sale -1,034 49,266 -2.06 24.16 -24,981 1,190,267
2014-06-02 2014-05-30 4 MKTO Marketo, Inc.
Common Stock
S - Sale -19,373 0 -100.00 23.20 -449,454
2014-06-02 2014-05-29 4 MKTO Marketo, Inc.
Common Stock
S - Sale -22,090 16,613 -57.08 24.57 -542,751 408,181
2014-06-02 2014-05-29 4 MKTO Marketo, Inc.
Common Stock
S - Sale -23,133 50,300 -31.50 24.57 -568,378 1,235,871
2014-06-02 2014-05-29 4 MKTO Marketo, Inc.
Common Stock
S - Sale -9,118 0 -100.00 24.56 -223,938
2014-06-02 2014-05-29 4 MKTO Marketo, Inc.
Common Stock
S - Sale -11,298 0 -100.00 24.59 -277,818
2014-06-02 2014-05-29 4 MKTO Marketo, Inc.
Common Stock
S - Sale -21,821 19,373 -52.97 24.58 -536,360 476,188
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 10,933 38,703 39.37
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 11,298 11,298
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 9,118 9,118
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 8,532 30,204 39.37
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 25,597 41,194 164.11
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 34,130 120,819 39.37
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 26,393 73,433 56.11
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other -194,800 0 -100.00
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other 194,800 194,800
2014-05-30 2014-05-28 4 MKTO Marketo, Inc.
Common Stock
J - Other -974,000 3,715,756 -20.77
2014-05-22 2014-05-21 4 MKTO Marketo, Inc.
Common Stock
S - Sale -5,000 15,597 -24.28 24.00 -120,000 374,328
2014-05-22 2014-05-20 4 MKTO Marketo, Inc.
Common Stock
S - Sale -5,000 20,597 -19.53 24.02 -120,090 494,699
2014-05-20 2014-05-16 4 MKTO Marketo, Inc.
Common Stock
S - Sale -15,000 25,597 -36.95 22.96 -344,427 587,753
2014-05-15 2014-05-14 4 MKTO Marketo, Inc.
Common Stock
S - Sale -8,463 0 -100.00 24.34 -206,006
2014-05-15 2014-05-13 4 MKTO Marketo, Inc.
Common Stock
S - Sale -14,695 8,463 -63.46 24.26 -356,467 205,293
2014-05-15 2014-05-13 4 MKTO Marketo, Inc.
Common Stock
S - Sale -11,298 0 -100.00 24.25 -273,954
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 10,933 27,770 64.93
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 11,298 11,298
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 9,118 23,158 64.94
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 8,532 21,672 64.93
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 25,597 40,597 170.65
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 34,130 86,689 64.94
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 26,393 47,040 127.83
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other -194,800 0 -100.00
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 194,800 194,800
2014-05-14 2014-05-12 4 MKTO Marketo, Inc.
Common Stock
J - Other -974,000 4,689,756 -17.20
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Common Stock Warrant
C - Conversion 11,895 11,895
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Series B-1 Warrant
C - Conversion -416,361 0 -100.00
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Series B-3 Convertible Preferred Stock
C - Conversion -5,699,111 0 -100.00
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Series B-2 Convertible Preferred Stock
C - Conversion -11,893,926 0 -100.00
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Series B-1 Convertible Preferred Stock
C - Conversion -6,409,436 0 -100.00
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Series A-1 Convertible Preferred Stock
C - Conversion -11,479,011 0 -100.00
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Common Stock
P - Purchase 75,376 1,452,216 5.47 12.00 904,512 17,426,592
2014-04-01 2014-04-01 4 AGTC APPLIED GENETIC TECHNOLOGIES CORP
Common Stock
C - Conversion 1,376,480 1,376,480
2014-03-03 2014-02-28 4 MKTO Marketo, Inc.
Common Stock
S - Sale -5,000 15,000 -25.00 41.56 -207,800 623,400
2014-03-03 2014-02-27 4 MKTO Marketo, Inc.
Common Stock
S - Sale -19,420 20,000 -49.26 42.06 -816,805 841,200
2014-02-28 2014-02-26 4 MKTO Marketo, Inc.
Common Stock
S - Sale -13,050 0 -100.00 40.03 -522,392
2014-02-28 2014-02-26 4 MKTO Marketo, Inc.
Common Stock
S - Sale -20,000 20,647 -49.20 40.62 -812,400 838,681
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 12,628 16,837 300.02
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 13,050 13,050
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 10,530 14,040 300.00
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 9,855 13,140 300.00
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 29,565 39,420 300.00
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 39,420 52,559 300.02
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 30,485 40,647 299.99
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other -225,000 0 -100.00
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other 225,000 225,000
2014-02-27 2014-02-25 4 MKTO Marketo, Inc.
Common Stock
J - Other -1,500,000 5,663,756 -20.94
2014-02-18 2014-02-13 4 MKTO Marketo, Inc.
Common Stock
S - Sale -4,350 0 -100.00 40.70 -177,045
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 4,209 4,209
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 4,350 4,350
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 3,510 3,510
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 3,285 3,285
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 9,855 9,855
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 13,139 13,139
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 10,162 10,162
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other -75,000 0 -100.00
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other 75,000 75,000
2014-02-14 2014-02-12 4 MKTO Marketo, Inc.
Common Stock
J - Other -500,000 7,163,756 -6.52
2013-11-21 2013-11-20 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise -12,000 0 -100.00
2013-11-21 2013-11-20 4 XLNX XILINX INC
XLNX COMMON STOCK
S - Sale -10,644 78,060 -12.00 43.35 -461,456 3,384,182
2013-11-21 2013-11-20 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 12,000 88,704 15.64 38.51 462,120 3,415,991
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series D-2 Convertible Preferred Stock
C - Conversion -2,448 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series D-2 Convertible Preferred Stock Warrant to buy
X - Other -46,005 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series D-2 Convertible Preferred Stock
C - Conversion -613,402 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series C Convertible Preferred Stock
C - Conversion -5,547,611 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series B Convertible Preferred Stock
C - Conversion -10,131,856 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Series A-1 Convertible Preferred Stock
C - Conversion -12,001,000 0 -100.00
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Common Stock
C - Conversion 2,448 1,908,716 0.13
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Common Stock
C - Conversion 32,671 1,906,268 1.74
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Common Stock
C - Conversion 295,494 1,873,597 18.72
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Common Stock
C - Conversion 615,284 1,578,103 63.90
2013-10-18 2013-10-16 4 MGNX MACROGENICS INC
Common Stock
C - Conversion 962,819 962,819
2013-09-18 2013-09-18 4 MKTO Marketo, Inc.
Common Stock
S - Sale -2,083,435 7,663,756 -21.37 33.99 -70,818,664 260,501,029
2013-08-15 2013-08-14 4 XLNX XILINX INC
Restricted Stock Unit
A - Award 3,660 3,660
2013-08-15 2013-08-13 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -4,893 0 -100.00
2013-08-15 2013-08-13 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -4,893 76,704 -6.00
2013-08-15 2013-08-13 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 4,893 18,320 36.44
2013-08-15 2013-08-13 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 4,893 81,597 6.38
2013-08-07 2013-08-05 4 TSRO TESARO, Inc.
Common Stock
J - Other -600,000 2,471,701 -19.53
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Series F Convertible Preferred Stock
C - Conversion -227,272 0 -100.00
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Series E Convertible Preferred Stock
C - Conversion -394,714 0 -100.00
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Series D Convertible Preferred Stock
C - Conversion -570,977 0 -100.00
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Series B Convertible Preferred Stock
C - Conversion -3,154,228 0 -100.00
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Series A Convertible Preferred Stock
C - Conversion -5,400,000 0 -100.00
2013-05-22 2013-05-22 4 MKTO Marketo, Inc.
Common Stock
C - Conversion 9,747,191 9,747,191
2012-11-01 2012-10-31 4 XLNX XILINX INC
NQSO (Right to Buy)
M - Exercise -12,000 0 -100.00
2012-11-01 2012-10-31 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 12,000 76,704 18.55 22.03 264,360 1,689,789
2012-08-09 2012-08-08 4 XLNX XILINX INC
Restricted Stock Unit
A - Award 4,893 4,893
2012-08-09 2012-08-07 4 XLNX XILINX INC
Restricted Stock Unit
M - Exercise -4,783 0 -100.00
2012-08-09 2012-08-07 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift -4,783 64,704 -6.88
2012-08-09 2012-08-07 4 XLNX XILINX INC
XLNX COMMON STOCK
G - Gift 4,783 13,427 55.33
2012-08-09 2012-08-07 4 XLNX XILINX INC
XLNX COMMON STOCK
M - Exercise 4,783 69,487 7.39
2012-07-05 2012-07-03 4 TSRO TESARO, Inc.
Series B Preferred Stock
C - Conversion -9,195,402 0 -100.00
2012-07-05 2012-07-03 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 444,444 3,071,701 16.92 13.50 5,999,994 41,467,964
2012-07-05 2012-07-03 4 TSRO TESARO, Inc.
Common Stock
C - Conversion 2,627,257 2,627,257
2011-09-23 2011-09-21 4 TSPT Transcept Pharmaceuticals Inc
Common
P - Purchase 217,228 1,983,884 12.30 7.24 1,573,122 14,366,891
2011-09-22 3 TSPT Transcept Pharmaceuticals Inc
Common
1,766,656
2007-11-21 2007-11-20 4 ETRM EnteroMedics Inc
Series C Preferred Stock
C - Conversion -1,359,261 0 -100.00
2007-11-21 2007-11-20 4 ETRM EnteroMedics Inc
Common Stock
C - Conversion 1,359,261 1,546,761 724.94
2007-11-19 2007-11-15 4 ETRM EnteroMedics Inc
Common Stock
P - Purchase 187,500 187,500 8.00 1,500,000 1,500,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)